Close Menu

cell-based diagnostics

The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.

The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.

The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.

The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.

Novacyt will use the financing to accelerate the launch of its NovaPrep system inChinawith its distribution partner Leica Biosystems.

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

A prospective study slated for publication has demonstrated that Precision Therapeutics' ChemoFx test was able to predict whether ovarian cancer patients would live longer if they took a particular chemotherapy.

NEW YORK (GenomeWeb News) – MBio Diagnostics today said that it has achieved ISO 13485:2003 certification for its quality management system.

NEW YORK (GenomeWeb News) – A group of Swiss partners today announced a collaboration to develop, use, and promote a flow cytometry data analysis platform.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.